Metabolic syndrome represents a common risk factor for premature cardiovascular disease and cancer whose core cluster includes diabetes, hypertension, dyslipidaemia and obesity. The liver is a target organ in metabolic syndrome patients in which it manifests itself with nonalcoholic fatty liver disease spanning steatosis through hepatocellular carcinoma via steatohepatitis and cirrhosis. Given that metabolic syndrome and non-alcoholic fatty liver disease affect the same insulin-resistant patients. not unexpectedly, there are amazing similarities between metabolic syndrome and non-alcoholic fatty liver disease in terms of prevalence, pathogenesis, clinical features and outcome. The available drug weaponry for metabolic syndrome includes aspirin, metformin, peroxisome proliferator-activated receptor agonists, statins, ACE (angiotensin I-converting enzyme) inhibitors and sartans, which are potentially or clinically useful also to the non-alcoholic fatty liver disease patient. Studies are needed to highlight the grey areas in this topic. Issues to be addressed include: diagnostic criteria for metabolic syndrome; nomenclature of non-alcoholic fatty liver disease; enlargement of the clinical spectrum and characterization of the prognosis of insulin resistance-related diseases: evaluation of the most specific clinical predictors of metabolic syndrome/non-alcoholic fatty liver disease and assessment of their variability over the time; characterization of the importance of new risk factors for metabolic syndrome with regard to the development and progression of non-alcoholic fatty liver disease.

Review article: the metabolic syndrome and non-alcoholic fatty liver disease / Loria, Paola; A., Lonardo; Carulli, Lucia; Am, Verrone; Ricchi, Matteo; S., Lombardini; A., Rudilosso; Ballestri, Stefano; Carulli, Nicola. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - ELETTRONICO. - 22:2(2005), pp. 31-36. [10.1111/j.1365-2036.2005.02592.x]

Review article: the metabolic syndrome and non-alcoholic fatty liver disease

LORIA, Paola;CARULLI, Lucia;RICCHI, Matteo;BALLESTRI, Stefano;CARULLI, Nicola
2005

Abstract

Metabolic syndrome represents a common risk factor for premature cardiovascular disease and cancer whose core cluster includes diabetes, hypertension, dyslipidaemia and obesity. The liver is a target organ in metabolic syndrome patients in which it manifests itself with nonalcoholic fatty liver disease spanning steatosis through hepatocellular carcinoma via steatohepatitis and cirrhosis. Given that metabolic syndrome and non-alcoholic fatty liver disease affect the same insulin-resistant patients. not unexpectedly, there are amazing similarities between metabolic syndrome and non-alcoholic fatty liver disease in terms of prevalence, pathogenesis, clinical features and outcome. The available drug weaponry for metabolic syndrome includes aspirin, metformin, peroxisome proliferator-activated receptor agonists, statins, ACE (angiotensin I-converting enzyme) inhibitors and sartans, which are potentially or clinically useful also to the non-alcoholic fatty liver disease patient. Studies are needed to highlight the grey areas in this topic. Issues to be addressed include: diagnostic criteria for metabolic syndrome; nomenclature of non-alcoholic fatty liver disease; enlargement of the clinical spectrum and characterization of the prognosis of insulin resistance-related diseases: evaluation of the most specific clinical predictors of metabolic syndrome/non-alcoholic fatty liver disease and assessment of their variability over the time; characterization of the importance of new risk factors for metabolic syndrome with regard to the development and progression of non-alcoholic fatty liver disease.
2005
22
2
31
36
Review article: the metabolic syndrome and non-alcoholic fatty liver disease / Loria, Paola; A., Lonardo; Carulli, Lucia; Am, Verrone; Ricchi, Matteo; S., Lombardini; A., Rudilosso; Ballestri, Stefano; Carulli, Nicola. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - ELETTRONICO. - 22:2(2005), pp. 31-36. [10.1111/j.1365-2036.2005.02592.x]
Loria, Paola; A., Lonardo; Carulli, Lucia; Am, Verrone; Ricchi, Matteo; S., Lombardini; A., Rudilosso; Ballestri, Stefano; Carulli, Nicola
File in questo prodotto:
File Dimensione Formato  
loria APT .pdf

Solo gestori archivio

Tipologia: Versione pubblicata dall'editore
Dimensione 65.69 kB
Formato Adobe PDF
65.69 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/304730
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 58
  • ???jsp.display-item.citation.isi??? 48
social impact